Heart failure trial Teva spending 100 million so they are very interested first trial analysis 125 patients second quarter.
GVHD not being marketed at present in New Zealand and Canada and the approval is for children and adults.
Rheumatoid arthritis has potential for early market approval subject to new laws in Japan.
Osiris had issues but Mesoblast has moved on with making changes to there technology.Obvious it works other wise they would not have purchased Osiris!
Ann: Change in substantial holding, page-19
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |